Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Hepatitis B Virus infection in mammals, and to methods of using those compositions of matter for the same.
Type:
Grant
Filed:
July 19, 2018
Date of Patent:
November 28, 2023
Assignee:
THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
Inventors:
Paul T. Wingfield, Norman R. Watts, Alasdair C Steven
Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making the anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.
Type:
Grant
Filed:
November 11, 2020
Date of Patent:
November 28, 2023
Assignee:
Vitaeris Inc.
Inventors:
Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T. L. Smith
Abstract: The invention relates to PD-1 binding agents that do not block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.
Type:
Grant
Filed:
January 8, 2018
Date of Patent:
November 14, 2023
Assignee:
CRESCENDO BIOLOGICS LIMITED
Inventors:
Bryan Edwards, Carolyn Edwards, James Legg, Martyna Lewandowska, Daniela Sydoruk, Colette Johnston, Christine Rossant, Yumin Teng
Abstract: The present invention relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human ?-klotho, and pharmaceutical compositions and methods of treatment comprising the same.
Type:
Grant
Filed:
December 1, 2021
Date of Patent:
October 31, 2023
Assignee:
Novartis AG
Inventors:
Brian Boettcher, Shari Lynn Caplan, Regis Cebe, Guochun Li, John A. Taraszka, Fangmin Xu, David Langdon Yowe
Abstract: The present disclosure provides anti-EGFR antibody polypeptides, polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.
Abstract: This application discloses ophthalmic formulations and methods for treating and preventing corneal haze and scarring with an hepatocyte growth factor (HGF) agent.
Type:
Grant
Filed:
April 20, 2021
Date of Patent:
September 19, 2023
Assignee:
The Schepens Eye Research Institute, Inc.
Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).
Type:
Grant
Filed:
March 12, 2021
Date of Patent:
September 19, 2023
Assignee:
Genentech, Inc.
Inventors:
Gerald R. Nakamura, Dhaya Seshasayee, Menno Van Lookeren Campagne, Tiffany Wong, Jia Wu, Hongkang Xi, Jack Bevers, III, Hiu Nam Chan, Laetitia Comps-Agrar, Racquel Corpuz
Abstract: The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.
Type:
Grant
Filed:
September 3, 2021
Date of Patent:
August 22, 2023
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Roland Beckmann, Sebastian Fenn, Guido Hartmann, Sabine Imhof-Jung, Kristian Hobolt-Jensen, Joerg Moelleken, Michael Molhoj, Christian Schantz, Janina Speck, Christoph Ullmer, Barbara Weiser
Abstract: Provided herein are polypeptides that bind to a blood-brain barrier (BBB) receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a BBB receptor-expressing cell, e.g., for transport across the BBB. Also provided herein are transferrin receptor (TfR) constructs that comprise a monomeric TfR apical domain or one or more portions of the TfR apical domain which have been circularly permuted relative to the full-length TfR sequence.
Type:
Grant
Filed:
September 17, 2019
Date of Patent:
August 22, 2023
Assignee:
Denali Therapeutics Inc.
Inventors:
Xiaocheng Chen, Mihalis Kariolis, Robert C. Wells
Abstract: Provided are constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes PD-1. Also provided are methods of making and using these constructs.
Type:
Grant
Filed:
January 15, 2019
Date of Patent:
August 1, 2023
Assignee:
Nanjing Legend Biotech Co., Ltd.
Inventors:
Yafeng Zhang, Shu Wu, Shuai Yang, Chuan-Chu Chou
Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
Abstract: The present disclosure relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human ?-klotho, and pharmaceutical compositions and methods of treatment comprising the same.
Type:
Grant
Filed:
December 18, 2020
Date of Patent:
July 4, 2023
Assignee:
Novartis AG
Inventors:
Regis Cebe, Stephane Olland, David Langdon Yowe
Abstract: The present application provides constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes PD-L1. Also provided are methods of making and using these constructs.
Type:
Grant
Filed:
November 13, 2018
Date of Patent:
June 13, 2023
Assignee:
Nanjing Legend Biotech Co., Ltd.
Inventors:
Yafeng Zhang, Shu Wu, Shuai Yang, Chuan-Chu Chou
Abstract: The present disclosure relates to antibody molecules that bind specifically to C-MET and related nucleic acid molecules, vectors and host cells. Also provided are medical uses of such antibody molecules. The claimed anti C-Met antibodies of the present application have been selected by in silico engineering. Some of the antibodies have been generated and further characterized after expression in mammalian expression system.
Abstract: The disclosure relates to an anti-VEGF-PD1 bispecific antibody with a novel structure and a use thereof, which belongs to the technical field of molecular immunology. The CDR-H1 in the heavy chain variable region of the antibody is an amino acid sequence expressed by SEQ ID NO: 1, the CDR-H2 is an amino acid sequence expressed by SEQ ID NO: 2, the CDR-H3 is an amino acid sequence expressed by SEQ ID NO: 3, and the CDR-L in the light chain variable region of the antibody is an amino acid sequence expressed by SEQ ID NO:4.
Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
Type:
Grant
Filed:
December 23, 2013
Date of Patent:
May 9, 2023
Assignees:
Ablynx N.V., Sanofi
Inventors:
Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
Abstract: The present invention relates to compositions and methods for the prevention or the treatment of prostate cancer, wherein said compositions comprise an antibody binding to progastrin and said methods comprise the use of an antibody binding to progastrin.
Abstract: A method for treating or preventing vascular endothelial cell injured diseases, especially cerebral infarctions or myocardial infarctions, by administering a c-MET agonist antibody to a subject in need thereof, and specific c-MET agonist antibodies.
Type:
Grant
Filed:
October 31, 2018
Date of Patent:
April 25, 2023
Assignee:
TONGJI UNIVERSITY SUZHOU INSTITUTE BIOMEDICAL RESEARCH CENTER
Abstract: Compositions and methods for treating hair loss are provided. One embodiment provides a microneedle composition, which when administered to the skin of a subject promotes hair growth. The microneedle compositions include an effective amount of glucocorticoid-induced leucine zipper (GILZ) protein having an amino acid sequence that has 99 or 100% identity to SEQ ID NO: 1, or fragment thereof to promote hair growth when administered to the skin of the subject and a bioerodible, biodegradable, or biosorbable polymer, wherein the composition is formulated as bioerodible, biodegradable, or bioabsorbable microneedles. In one embodiment the GILZ protein or fragment thereof is conjugated to a cell penetrating peptide. The cell penetrating peptide can be TAT GRKKRRQRRRPQ (SEQ ID NO:4) or a variant thereof.
Type:
Grant
Filed:
October 11, 2019
Date of Patent:
April 25, 2023
Assignee:
Augusta University Research Institute, Inc.